Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
JNJ 
Johnson & Johnson (JNJ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: JNJ (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
24 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $174.92
1 Year Target Price $174.92
| 7 | Strong Buy |
| 4 | Buy |
| 13 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.62% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 420.79B USD | Price to earnings Ratio 18.69 | 1Y Target Price 174.92 |
Price to earnings Ratio 18.69 | 1Y Target Price 174.92 | ||
Volume (30-day avg) 24 | Beta 0.4 | 52 Weeks Range 138.38 - 177.26 | Updated Date 08/15/2025 |
52 Weeks Range 138.38 - 177.26 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 2.88% | Basic EPS (TTM) 9.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-16 | When Before Market | Estimate 2.68 | Actual 2.77 |
Profitability
Profit Margin 25% | Operating Margin (TTM) 28.91% |
Management Effectiveness
Return on Assets (TTM) 7.61% | Return on Equity (TTM) 30.21% |
Valuation
Trailing PE 18.69 | Forward PE 16.23 | Enterprise Value 451943466054 | Price to Sales(TTM) 4.64 |
Enterprise Value 451943466054 | Price to Sales(TTM) 4.64 | ||
Enterprise Value to Revenue 4.99 | Enterprise Value to EBITDA 12.68 | Shares Outstanding 2408339968 | Shares Floating 2404678197 |
Shares Outstanding 2408339968 | Shares Floating 2404678197 | ||
Percent Insiders 0.06 | Percent Institutions 74.25 |
Upturn AI SWOT
Johnson & Johnson
Company Overview
History and Background
Johnson & Johnson was founded in 1886 by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. Initially focused on sterile surgical dressings, it has grown into a diversified healthcare company with products ranging from consumer health to pharmaceuticals and medical devices.
Core Business Areas
- Innovative Medicine (Pharmaceutical): Discovers, develops, and markets innovative medicines to address serious health needs across several therapeutic areas, including immunology, oncology, neuroscience, cardiovascular & metabolism, and pulmonary hypertension.
- MedTech: Offers a broad portfolio of medical technology solutions used to address health needs across a range of surgical, orthopaedic, vision, and interventional solutions.
Leadership and Structure
Joaquin Duato is the current Chief Executive Officer. The company operates under a decentralized organizational structure, with each business segment having its own leadership team and profit and loss responsibility. The Board of Directors provides overall governance.
Top Products and Market Share
Key Offerings
- Stelara: A biologic therapy used to treat autoimmune diseases such as psoriasis, Crohn's disease, and ulcerative colitis. Its primary competitors are TNF inhibitors and other newer biologics like IL-23 inhibitors. Revenue for this drug for 2023 was in excess of $10 Billion USD. Stelara's market share within the relevant biologics market segment is significant.
- Darzalex: A monoclonal antibody used in the treatment of multiple myeloma. Competitors include other myeloma therapies from companies like Amgen and Bristol Myers Squibb. Revenue for this drug for 2023 was in excess of $7.9 Billion USD. Darzalex has captured a substantial market share within its treatment niche.
- Acclarent: Medical devices for ear, nose, and throat (ENT) specialists, especially in sinus health. Main competitors are Medtronic and Stryker. Acclarent holds a large share within the sinus health medical device field.
Market Dynamics
Industry Overview
The healthcare industry is characterized by high barriers to entry, intense competition, and significant regulatory oversight. It's driven by innovation, aging populations, and increasing healthcare spending.
Positioning
Johnson & Johnson is a leading player in the healthcare industry due to its diversified business model, strong brand recognition, and extensive research and development capabilities. It competes on innovation, product quality, and global reach.
Total Addressable Market (TAM)
The global healthcare market is valued at trillions of USD. Johnson & Johnson is well positioned within this TAM across its pharmaceutical, medical device and consumer health segments.
Upturn SWOT Analysis
Strengths
- Diversified revenue streams
- Strong brand reputation
- Extensive global reach
- Robust R&D pipeline
- Strong financial position
Weaknesses
- Exposure to litigation risk
- Patent expirations
- Product recalls
- Reliance on key products
- Integration challenges from acquisitions
Opportunities
- Emerging markets growth
- Aging population trends
- Technological advancements in healthcare
- Strategic acquisitions
- Partnerships with innovative biotech companies
Threats
- Generic competition
- Increased regulatory scrutiny
- Economic downturns
- Changing healthcare policies
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- PFE
- MRK
- ABBV
- BMY
- TMO
Competitive Landscape
Johnson & Johnson's diversified business model provides a competitive advantage. However, it faces intense competition in each of its business segments from companies with specialized expertise.
Major Acquisitions
Abiomed
- Year: 2022
- Acquisition Price (USD millions): 16600
- Strategic Rationale: Expanded J&J's MedTech portfolio in the cardiovascular space, providing access to innovative heart support and recovery technologies.
Growth Trajectory and Initiatives
Historical Growth: Johnson & Johnson's growth has been driven by a combination of organic growth and acquisitions. Growth rates have varied across different business segments.
Future Projections: Analyst estimates suggest moderate growth for Johnson & Johnson, driven by new product launches and expansion into emerging markets. Projections vary among analysts.
Recent Initiatives: Recent initiatives include strategic acquisitions, investments in R&D, and restructuring efforts to improve efficiency.
Summary
Johnson & Johnson is a well-established and diversified healthcare giant with a strong brand and global reach. Its diversified portfolio provides resilience, but the company faces challenges from patent expirations, litigation, and intense competition. The acquisition of Abiomed appears to be a boost to JNJ's MedTech offerings. Innovation and strategic capital allocation will be key to future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10K, 10Q)
- Company Website
- Analyst Reports
- Third-Party Market Research Reports
- Publicly Available Information
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market data is subject to change and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Johnson & Johnson
Exchange NYSE | Headquaters New Brunswick, NJ, United States | ||
IPO Launch date 1944-09-24 | CEO & Chairman Mr. Joaquin Duato | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 138100 | Website https://www.jnj.com |
Full time employees 138100 | Website https://www.jnj.com | ||
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.